Dr. Robert F. Ozols Elected Board Member of American Society of Clinical Oncology
PHILADELPHIA (February 22, 2000) -- The Board of Directors of the American Society of Clinical Oncology (ASCO), the leading association of clinical cancer researchers and practitioners, has announced that Robert F. Ozols, MD, PhD (Solebury, Pa), of Fox Chase Cancer Center has been elected as a new board member for ASCO. His three-year term begins in May.
Dr. Ozols is senior vice president for medical science at Fox Chase where he oversees all patient care, clinical research and medical-science laboratory research. He is also an associate dean of Temple University School of Medicine and program director for the joint oncology program by Fox Chase and Temple University Health System.
A leader in advancing chemotherapy research, Dr. Ozols is internationally recognized for his expertise in ovarian cancer. He has developed new clinical approaches to treating women with ovarian cancer, including new chemotherapy regimens that combine paclitaxel (Taxol) and carboplatin as well as pharmacologic techniques to reverse the tumor's resistance to anti-cancer drugs.
His laboratory research has focused on how cancer cells develop drug resistance and on strategies for overcoming it. Resistance to chemotherapy, which often occurs in patients with ovarian cancer, is a major treatment obstacle in a number of adult cancers.
The American Society of Clinical Oncology (ASCO) is the world's leading professional society representing physicians from 95 countries who treat people with cancer. ASCO's 14,000 members set the standard for patient care worldwide and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the myriad different cancers that strike 1.2 million Americans every year.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at: www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.